Abstract:Abstract Purpose: MicroRNAs (miRNA) can function as oncogenes or tumor suppressors. In this study, we test the hypothesis that genetic variation within miRNA processing genes or miRNA binding sites in cancer-related genes may alter clinical outcomes for non–small cell cancer (NSCLC) patients. Methods: We genotyped 72 single nucleotide polymorphisms (SNPs) from eight miRNA processing genes and 168 SNPs from 133 predicted miRNA binding sites in 535 patients with early stage (stages I, IIA, and IIB) NSCLC to determine the effect of these variations on progression risk and overall survival. We further conducted a subset analysis to exclude potential bias due to different treatment regimens. Results: In the analysis of overall survival, an FAS SNP remained significant for decreased risk after multiple comparisons in all early patients (HR: 0.59, 95% CI: 0.44–0.77; GG: MST = 58 mos, GA + AA: MST = 118 mos) and surgery plus chemotherapy subgroup (HR: 0.19, 95% CI: 0.07–0.46, P = 1.84 × 10−5; GG: MST = 65 mos, GA + AA: MST = 137 mos). In the surgery-only patients, an FZD4 SNP (HR: 0.46, 95% CI: 0.32–0.65; GG: MST = 59 mons, GA + AA: MST = 117 mos) had a significant protective effect after multiple comparisons adjustment. For progression risk, following multiple comparison, an SP1 SNP (HR: 2.19, 95% CI: 1.45–3.32; GG: MST > 270 mos, GA + AA: MST = 45 mos) and an MBD1 SNP (HR: 2.41, 95% CI: 1.45–4.0; AA: MST > 270 mos, C + CC: MST = 90 mos) remained significant increased progression risk in the entire and surgery only population respectively. All the associations significant after adjusting for multiple comparisons were validated by Bootstrap resampling method. A strong cumulative effect of these variant genotypes to increase risk and dramatically decrease median event-free time was consistently observed. We also identified potential higher-order gene–gene interactions among these SNPs. Conclusions: We identified significant association between miRNA-related genetic variants and early stage NSCLC patient clinical outcomes. With validation, our result can be used in the prognosis of clinical outcomes for early stage NSCLC patients.

Genetic Variation in a Microrna-502 Minding Site in SET8 Gene Confers Clinical Outcome of Non-Small Cell Lung Cancer in a Chinese Population.

An Mir-502-Binding Site Single-Nucleotide Polymorphism In The 3 '-Untranslated Region Of The Set8 Gene Is Associated With Early Age Of Breast Cancer Onset

A functional single nucleotide polymorphism of SET8 is prognostic for breast cancer.

A polymorphism at the miR-502 binding site in the 3' untranslated region of the SET8 gene is associated with the outcome of small-cell lung cancer

A Genetic Polymorphism In Pre-Mir-27a Confers Clinical Outcome Of Non-Small Cell Lung Cancer In A Chinese Population

MiR-502/SET8 Regulatory Circuit in Pathobiology of Breast Cancer

MiR-502/SET8 regulatory circuit in pathobiology of breast cancer.

Analysis of Genetic Variants and the Cerna Network of Mir-9 in Non-Small Cell Lung Cancer

Abstract A3: MicroRNA-related Polymorphisms Are Associated with Clinical Outcomes in Early Stage Non-Small Cell Lung Cancer Patients

MicroRNA-binding site SNPs in deregulated genes are associated with clinical outcome of non-small cell lung cancer

MicroRNA-Related Genetic Variants As Predictors of Early Stage Non–Small Cell Lung Cancer Clinical Outcomes

Genetic Polymorphisms in the Precursor MicroRNA Flanking Region and Non-Small Cell Lung Cancer Survival.

Variations Within 3′-UTR of MDM4 Gene Contribute to Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Following Platinum-Based Chemotherapy

Genetic variants in regulatory regions of microRNAs are associated with lung cancer risk.

Genetic variations in SLC3A2/CD98 gene as prognosis predictors in non-small cell lung cancer.

Genetic variations in <i>SLC3A2/CD98</i> gene as prognosis predictors in non‐small cell lung cancer

A Functional Variant in Mir-155 Regulation Region Contributes to Lung Cancer Risk and Survival

Genetic variations in monocarboxylate transporter genes as predictors of clinical outcomes in non-small cell lung cancer

Sequence Variation in Mature MicroRNA-499 Confers Unfavorable Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy.

Genetic Polymorphism of SLC31A1 is Associated with Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small-cell Lung Cancer Patients Through Modulating Microrna-Mediated Regulation.

Mir-492G>c Polymorphism (rs2289030) is Associated with Overall Survival of Hepatocellular Carcinoma Patients